title: Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization.
abstract: H. pylori drug-resistant strains and non-compliance to therapy are the major causes of H. pylori eradication failure. For some bacterial species it has been demonstrated that fatty acids have a growth inhibitory effect. Our main aim was to assess the ability of docosahexaenoic acid (DHA) to inhibit H. pylori growth both in vitro and in a mouse model. The effectiveness of standard therapy (ST) in combination with DHA on H. pylori eradication and recurrence prevention success was also investigated. The effects of DHA on H. pylori growth were analyzed in an in vitro dose-response study and n in vivo model. We analized the ability of H. pylori to colonize mice gastric mucosa following DHA, ST or a combination of both treatments. Our data demonstrate that DHA decreases H. pylori growth in vitro in a dose-dependent manner. Furthermore, DHA inhibits H. pylori gastric colonization in vivo as well as decreases mouse gastric mucosa inflammation. Addition of DHA to ST was also associated with lower H. pylori infection recurrence in the mouse model. In conclusion, DHA is an inhibitor of H. pylori growth and its ability to colonize mouse stomach. DHA treatment is also associated with a lower recurrence of H. pylori infection in combination with ST. These observations pave the way to consider DHA as an adjunct agent in H. pylori eradication treatment.
authors.affiliation: Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal.
authors.forename: Marta
authors.initials: M
authors.lastname: Correia
authors.forename: Valérie
authors.initials: V
authors.lastname: Michel
authors.forename: António A
authors.initials: AA
authors.lastname: Matos
authors.forename: Patrícia
authors.initials: P
authors.lastname: Carvalho
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Oliveira
authors.forename: Rui M
authors.initials: RM
authors.lastname: Ferreira
authors.forename: Marie-Agnès
authors.initials: MA
authors.lastname: Dillies
authors.forename: Michel
authors.initials: M
authors.lastname: Huerre
authors.forename: Raquel
authors.initials: R
authors.lastname: Seruca
authors.forename: Ceu
authors.initials: C
authors.lastname: Figueiredo
authors.forename: Jose C
authors.initials: JC
authors.lastname: Machado
authors.forename: Eliette
authors.initials: E
authors.lastname: Touati
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D005753:Gastric Mucosa / Q000382:microbiology* / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000648:ultrastructure; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL
chemical_list: D000900:Anti-Bacterial Agents; D004281:Docosahexaenoic Acids